Saturday 17 October 2026
Export HLN’s income statement to Excel — free account
Haleon PLC Sponsored ADR
HLN Healthcare Drug Manufacturers Specialty & Generic
Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024. Revenue growth for three consecutive years, operating cash flow growth for three.
10.13
0.19
+1.91%
Follow HLN
| Older periods | Jun '24 | Sep '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+6 more quarters Free account |
— | 23.58 | — | — |
P/S ratio |
— | 2.69 | — | — | |
P/FCF ratio |
— | 10.42 | — | — | |
P/Operating CF |
— | 0.00 | — | — | |
P/B ratio |
— | 2.31 | — | — | |
Price to Tangible BV |
— | 0.00 | — | — | |
EV/Sales |
— | 3.27 | — | — | |
EV/EBITDA |
— | 13.92 | — | — | |
EV/Operating CF |
— | 10.95 | — | — | |
EV/FCF |
— | 12.67 | — | — | |
Quick Ratio |
0.49 | — | 0.61 | 0.51 | |
Current Ratio |
0.84 | — | 0.87 | 0.69 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
26.52% | 0.00% | 26.64% | 25.33% | |
Debt/Equity |
0.53 | — | 0.53 | 0.50 | |
Asset Turnover |
0.00 | 0.85 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
1.43 | — | (0.73) | (0.71) | |
Interest Coverage |
— | 7.83 | — | — | |
Research and Development Expense of Revenue |
— | 2.73% | — | — | |
Selling, General and Administrative Expense of Revenue |
— | 39.24% | — | — | |
Intangible Assets out of Total Assets |
0.79 | 0.00 | 0.80 | 0.79 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
— | (0.31) | — | — | |
Graham Number |
— | 0.00 | — | — | |
Earnings Yield |
— | 4.24% | — | — | |
Free Cash Flow Yield |
— | 9.60% | — | — | |
Revenue per Share |
— | 0.00 | — | — | |
Operating CF per Share |
0.00 | — | 0.00 | 0.00 | |
Capex per Share |
0.00 | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | — | 0.00 | 0.00 | |
Cash per Share |
0.00 | — | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | — | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | — | 0.00 | 0.00 | |
Book value per Share |
0.00 | — | 0.00 | 0.00 | |
Free Cash Flow |
1,339.09 | — | 1,199.37 | 1,241.44 | |
Working Capital |
(1,153.56) | — | (828.07) | (2,621.12) | |
Capital Expenditures |
276.40 | — | (172.29) | (159.71) | |
Net Current Asset Value |
(15,118.70) | — | (15,607.82) | (15,903.89) | |
EV/EBIT |
— | 18.22 | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | 14.98 | — | — | |
| Other line items | |||||
Average Receivables |
— | — | 3,085.27 | 2,798.30 | |
Average Payables |
— | — | 4,604.71 | 4,786.71 | |
Average Inventory |
— | — | 1,475.90 | 1,552.37 | |
Average Assets |
21,074.55 | 21,388.38 | 49,506.63 | 43,394.82 | |
Average Common Equity |
— | — | 27,632.09 | 21,209.90 |
Columns are period end dates